STOCKHOLM, Sweden--(BUSINESS WIRE)--Biovitrum examines a novel method for treating pain in a phase II clinical trial. The treatment aims at neuropathic pain, which is a chronic form of pain resulting from nerve injuries. Contrary to current treatments that act in the brain, Biovitrum´s substance is expected to act peripherally, directly in the injured nerve. There is a very large unmet medical need in this area. The market is estimated to approximately SEK 18 billion. The study is expected to include up to 300 patients and results are expected during the first half of 2008.
